MarginsXMarginsX
Home › Markets › Health Care › CNTX

Context Therapeutics Inc. (CNTX)

CNTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.1659
-8.24% on the day
Market cap
$15.2M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerCNTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001842952
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
12.2 months
$34.4M cash at September 30, 2026
Share count, 1 year
0.0%
2025-11-04 to 2026-11-06 · +475.5% over 3 years
Going-concern doubt
Yes
10-Q filed November 10, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"As a result, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that these consolidated financial statements are issued."
10-Q 2026-11-10
Cash and burn$34.4M cash; operating cash flow -$8.5M a quarter.Report 2026-09-30
Shares outstanding91,879,177 (2026-11-06); 91,879,177 a year earlier; 15,966,053 three years earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-07-31
AuditorCohnReznick LLP, Parsippany, New Jersey, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$7.6M-$6.6M$34.4MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$14.6M-$7.0M$43.0MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2026
2026-03-31
Not filed-$8.7M-$11.4M$54.5MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2025
2025-12-31
Not filed-$13.0M-$8.9M$66.0MNo debt tagsNeeds four quarters10-K 2026-03-23
Q3 2025
2025-09-30
Not filed-$9.7M-$6.6M$76.9MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2025
2025-06-30
Not filed-$8.8M-$5.8M$83.5MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2025
2025-03-31
Not filed-$4.6M-$5.0M$89.4MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2024
2024-12-31
Not filed-$3.3M-$4.9M$94.4MNo debt tagsNeeds four quarters10-K 2026-03-23

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-10-24
Latest annual report10-K2026-03-23
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 309 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.7%
1 month-34.2%
3 months-64.2%
Year to date-87.7%
1 year-84.3%
From 52-week high-94.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
AKTXAkari Therapeutics plc ADS$6.51-4.26%$15.1M
BOLTBolt Biotherapeutics Inc.$5.80-4.61%$15.1M
PBMPsyence Biomedical Ltd. Common Shares$2.83-11.56%$15.0M
ACTUActuate Therapeutics Inc.$0.2680-7.59%$14.7M
TVRDTvardi Therapeutics Inc.$1.10-6.78%$14.7M
NCELNewcelX Ltd.$2.75+5.36%$15.9M
CTXRCitius Pharmaceuticals Inc.$0.5276-1.40%$14.5M
MCRBSeres Therapeutics Inc.$1.41+0.71%$14.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier